跳转至内容
Merck
CN
所有图片(2)

文件

安全信息

HBNMAG-51K

Millipore

MILLIPLEX® 人骨磁珠板 - 骨代谢多重检测

The analytes available for this multiplex kit are: ACTH, DKK-1, FGF-23, IL-1β, IL-6, Insulin, Leptin, Osteocalcin, OPN - Osteopontin, Osteoprotegerin, PTH, SOST, TNF-α.

登录查看公司和协议定价
所有图片(2)
别名:
human bone metabolic biomarkers immunoassay panel, luminex human bone metabolism multiplex assay, millipore human bone metabolic biomarkers multiplex kit
UNSPSC代码:
12161503
eCl@ss:
32161000
NACRES:
NA.84

质量水平

200

种属反应性

human

制造商/商品名称

Milliplex®

assay range

accuracy: 82-97%
standard curve range: 0.24-1,000 pg/mL
(TNFα)
standard curve range: 1-3,000 pg/mL
(IL-1β)
standard curve range: 1-6,000 pg/mL
(ACTH & IL-6)
standard curve range: 146-600,000 pg/mL
(OC)
standard curve range: 24-100,000 pg/mL
(SOST)
standard curve range: 37-150,000 pg/mL
(FGF-23)
standard curve range: 49-200,000 pg/mL
(Leptin)
standard curve range: 5-20,000 pg/mL
(DKK-1)
standard curve range: 5-20,000 pg/mL
(PTH)
standard curve range: 61-250,000 pg/mL
(Insulin)
standard curve range: 7-30,000 pg/mL
(OPG)
standard curve range: 98-400,000 pg/mL
(OPN)

技术

multiplexing: suitable

检测方法

fluorometric (Luminex xMAP)

运输

wet ice

相关类别

一般描述

骨代谢是由成骨细胞，骨细胞和破骨细胞控制的正在进行的骨沉积和吸收的动态过程。而成骨细胞和骨细胞（被基质包围的成骨细胞）负责骨沉积，而破骨细胞则负责骨吸收。两者都需要维持骨骼结构以及充足的钙供应。为了维持这种代谢平衡，这些细胞依赖于涉及激素和细胞因子的复杂信号传导途径来实现适当的生长和分化速率。骨代谢紊乱可导致骨质疏松症、骨关节炎、类风湿关节炎、慢性肾脏疾病和骨转移等疾病。

MILLIPLEX®人骨磁珠试剂盒用于同时定量人血浆、血清或组织/细胞裂解物和培养上清液样品中以下分析物的任何或全部：促肾上腺皮质激素（ACTH)，Dickkopf-1（DKK1），IL-6，胰岛素，瘦素，TNFα，骨质疏松蛋白（OPG），骨钙素（OC），骨桥蛋白（OPN），硬化蛋白（SOST），IL-1β，甲状旁腺素（PTH）和FGF-23。该试剂盒采用96孔板，包含冻干标准混合物、两个内部检测质控品，可最多可测定38份样本，重复两次。

Luminex® xMAP®平台使用磁珠免疫分析格式，以实现理想的速度和灵敏度，同时定量多种分析物，从而显著提高生产力，同时节省宝贵的样本量。

面板类型：骨

特异性

交叉反应
对于该面板中的分析物，未观察到抗体之间的交叉反应性。

应用

  • 分析物：ACTH、DKK-1、FGF-23、IL-1β、IL-6、胰岛素、瘦素、骨钙素（OC）、骨桥蛋白（OPN）、骨保护素（OPG）、PTH、硬化蛋白（SOST）、TNFα
  • 推荐的样品类型：人血清，血浆和细胞/组织培养上清液或提取物
  • 建议的样品稀释度：每孔25μL d1:2稀释的血清或血浆；细胞/组织培养样品可以直接使用或在适当的对照培养基中稀释使用
  • 分析运行时间：在2-8℃下过夜（16-18小时）或在室温（20-25℃）下2小时。
  • 研究类别：代谢
  • 研究子类别：骨

特点和优势

通过在此面板中选择可用的分析物来设计多重试剂盒。

联系

替代：HBN1B-51K

其他说明

灵敏度：有关单个分析物的灵敏度，请参见试剂盒方案。
请联系技术服务部进行稀释度线性研究。

法律信息

Luminex is a registered trademark of Luminex Corp
MILLIPLEX is a registered trademark of Merck KGaA, Darmstadt, Germany
xMAP is a registered trademark of Luminex Corp

警示用语：

Danger

危险分类

Acute Tox. 3 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral - Aquatic Chronic 2 - Eye Dam. 1 - Skin Sens. 1 - STOT RE 2

靶器官

Respiratory Tract

WGK

WGK 3

法规信息

新产品

分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ （Lot或Batch）字后找到。

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Chiara Giannasi et al.
International journal of medical sciences, 16(1), 23-32 (2019-01-22)
Bisphosphonates (BPs) represent the first-line treatment for a wide array of bone disorders. Despite their well-known action on osteoclasts, the effects they induce on osteoblasts are still unclear. In order to shed light on this aspect we evaluated the impact
Edward R Smith et al.
Scientific reports, 7(1), 5686-5686 (2017-07-20)
Calciprotein particles, nanoscale aggregates of insoluble mineral and binding proteins, have emerged as potential mediators of phosphate toxicity in patients with Chronic Kidney Disease. Although existing immunochemical methods for their detection have provided compelling data, these approaches are indirect, lack
Sharon M Moe et al.
Circulation, 132(1), 27-39 (2015-06-11)
Patients with kidney disease have disordered bone and mineral metabolism, including elevated serum concentrations of fibroblast growth factor-23 (FGF23). These elevated concentrations are associated with cardiovascular and all-cause mortality. The objective was to determine the effects of the calcimimetic cinacalcet
Chia-Liang Tsai et al.
Experimental physiology, 102(12), 1683-1699 (2017-10-07)
What is the central question of this study? Obesity is linked to cognitive deficits, elevated energy metabolic indices and low-grade systemic inflammation. Do the relationships between neurocognitive performance and the biochemical markers (e.g. energy metabolic indices and inflammatory cytokines) occur
Ravit Regev et al.
Bone reports, 14, 100747-100747 (2021-01-29)
MCTO is a rare disorder, caused by mutations in the MafB gene, a negative regulator of receptor activator of nuclear factor-кB ligand (RANKL). Manifestations include carpal and tarsal osteolysis and renal failure. Pathophysiology is poorly understood, and no effective treatment
查看所有相关文献

相关内容

MILLIPLEX® PLEXpedition Multiplex Biomarker Screening Panel

Simplify protein biomarker discovery with the MILLIPLEX® PLEXpedition 115-Plex Multiplex Screening Panel. Effortlessly screen cytokines and other markers with Luminex® technology.

Multiplexing Tips & Tricks

UnEnhance research with MILLIPLEX® multiplexing tips, industry guidance, and one-day assays for limited lab time.

Multiplexing Metabolic Syndrome Biomarkers | MILLIPLEX® Assays

Multiplex immunoassays, such as MILLIPLEX® multiplex metabolic assays, are critical in metabolic syndrome research because they provide a full picture of the different conditions related to it, like diabetes and obesity, as well as save time and sample volume.

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门